POMDOCTOR Ltd (POM)
As-reported financials and SEC filings for POMDOCTOR Ltd. The latest annual period is FY2025. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About POMDOCTOR Ltd
POMDOCTOR Ltd operates an online medical services platform in China focused on chronic disease management and pharmaceutical services. The platform connects patients with contracted doctors for online consultations and prescription renewals, primarily serving patients with ongoing medical needs. It supports over 210,000 doctors and facilitates millions of prescriptions, aiming to improve access to healthcare and streamline chronic disease treatment.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at POMDOCTOR
- Free cash flow was negative $21M in FY2025.
- Net income was -$19M in FY2025.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where POMDOCTOR’s fundamentals sit among the 403 Consumer Discretionary companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
POMDOCTOR’s FCF margin of -37.4% ranks in the 3rd percentile of the 351 Consumer Discretionary companies reporting it. POMDOCTOR’s net margin of -32.7% ranks in the 5th percentile of the 377 Consumer Discretionary companies reporting it. POMDOCTOR’s operating margin of -29.7% ranks in the 6th percentile of the 348 Consumer Discretionary companies reporting it.
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Institutional ownership
Held by 1 quant / multi-strat book among the superinvestors we track; no conviction manager currently reports a position.
| Investor | As of | Position value | Shares | Change |
|---|---|---|---|---|
| Citadel Advisorsquant | Q2 2026 | $30,846 | 21.3K | New |
From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-08-14 | 26.0K | +36.4% | 1.00 |
| 2026-07-31 | 19.0K | -22.2% | 1.00 |
| 2026-07-15 | 24.5K | -67.1% | 1.00 |
| 2026-06-30 | 74.4K | -83.3% | 1.00 |
| 2026-06-15 | 444.4K | -23.6% | 1.00 |
| 2026-05-29 | 581.3K | -52.4% | 1.00 |
| 2026-05-15 | 1.2M | +74.0% | 1.00 |
| 2026-04-30 | 701.4K | +200.4% | 1.00 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | |
|---|---|
| Cash and equivalents | $1.4M |
| Current assets | $15.0M |
| Total assets | $15.4M |
| Current liabilities | $31.2M |
| Long-term debt | $11.7M |
| Total liabilities | $84.2M |
| Total equity | $-68.8M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Cash flow (as reported)
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.
Company facts
Selected SEC filings
Largest Consumer Discretionary peers
Monitor POM
Get an alert when POMDOCTOR files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor POM freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.